Selection of current research in progress
- The Effects of Cost-sharing on Health Care and Prescription Drug Utilization
There are still gaps to fill in the understanding of how cost-sharing affects health care utilization and prescription drugs, especially in the context of a tax-based health care system like the Swedish. We are conducting a couple of different studies where we use quasi-experimental approaches (regression-kink and regression-discontinuity designs) to estimate the causal impact of cost-sharing on consumption and utilization.
The aim of this project is to analyze how copayments affect the frequency of outpatient visits, with a focus on young adults. We will also study if individual demographic and socio-economic factors, such as gender, family, ethnic background, education and income, as well as the type of health care matter for the (potential) effect of patient copayments.
The result will bring valuable knowledge of how patient copayments affect health care utilization, which is important when assessing the consequences of health financing policies, in efficiency and equity perspective.
- Regional Variation in Health Care Utilization
Across geographical entities (countries, states, regions, communes) differences in health, health care utilization and health care expenditure have been observed. Differences in health care utilization and spending are considered valid if different entities have different needs, i.e. if people in one region are in general very healthy we would expect a lower level of health care utilization than a region with generally less healthy people. On the other hand, if the variation across entities cannot be explained by differences in need and preferences, it can be a sign of misallocation of resources, unnecessary overuse and inefficiency.
Regional variation across county councils is present also in Swedish health and health care, where in 2015 the county council average number of visits to a physician in primary care ranged from 1.1 to 2.0, and visits to an outpatient specialist ranged from 0.9 to 1.6. We are running a project where we try to disentangle the share of regional differences in health care utilization that can be explained by demand- and supply-factors, respectively.
- SWEDEPAD Cost-Effectivenss Analyses
We are conducting cost-effectiveness analyses as a part of the larger SWEdish Drug-Elution trial in Peripheral Arterial Disease (SWEDEPAD) study. The trial is a multi-site prospective register-randomized controlled trial.
- Cost-Effectiveness and Primary Care Treatments for Mild to Moderate Depression
We are conducting